¾«¶«Ó°Òµ

¾«¶«Ó°ÒµLimited (Headquaters: London, Managing Director: Paul Hooper), the U.K. subsidiary of ¾«¶«Ó°Òµ. (Headquarters: Tokyo, President & CEO: Haruo Naito), today announced that the company has tentatively withdrawn its application for an additional indication for Aricept® in the treatment of severe Alzheimer's disease, submitted through the mutual recognition procedure in Europe. ¾«¶«Ó°Òµwill discuss the matter with the European regulatory authorities and review possibilities for resubmission.

The Aricept®'s indication in the treatment of severe Alzheimer's disease has already been approved in the USA, India, New Zealand and Philippines. In addition, the application has been submitted in Japan.

¾«¶«Ó°Òµwill continue to undertake activities to help patients who are suffering from Alzheimer's disease.